Zoetis (NYSE:ZTS) Reaches New 1-Year Low – Time to Sell?

Shares of Zoetis Inc. (NYSE:ZTS) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $70.54 and last traded at $70.6070, with a volume of 434683 shares. The stock had previously closed at $71.40.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ZTS shares. BNP Paribas Exane decreased their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Citigroup cut their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research report on Tuesday, August 25th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $101.08.

Zoetis Price Performance

The stock’s 50-day moving average is $75.20 and its 200 day moving average is $88.98. The stock has a market capitalization of $30.07 billion, a PE ratio of 11.99, a P/E/G ratio of 1.66 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the firm earned $1.76 EPS. The company’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.

Institutional Investors Weigh In On Zoetis

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis during the first quarter valued at approximately $28,000. Root Financial Partners LLC lifted its position in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Wellington Grp LLC lifted its position in Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the period. Global Assets Advisory LLC bought a new stake in Zoetis in the 1st quarter valued at $38,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis in the 2nd quarter valued at $25,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.